Month: February 2022

Container Closure Integrity Testing for Pharmaceutical Industry

Over the past few years, the pharmaceutical industry is growing a tremendous pace. Considering patient’s health and safety, the drug products are expected to be free from microbial contamination and should be safe for use throughout the drug’s life cycle. Therefore, several quality checks are performed to ensure product’s sterility and stability. One of the

DNA Replication Demand: Driving Contract Manufacturing Market

Since the approval of the first antisense therapy in 1998, DNA replication has been in light for their capabilities as therapeutic agents. DNA replication provides a short synthetic nucleotide chain with immense potential in the diagnosis and treatment of a myriad of disease indications. In addition to therapeutics, these complex molecules act as a significant

Next Generation Sequencing: Revolutionizing the Field of Genetics

Next generation sequencing has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to better understand the cause and consequences of disease and develop next generation drug conjugates. Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and

Auto Injector: The Rising Need

With the increasing global population, the incidence rates of several chronic disease indications, such as diabetes, anaphylaxis, rheumatoid arthritis and psoriasis, are on the rise. This has led to a rise in the demand for effective treatment options for patients suffering from these diseases. Further, in order to improve the quality of life in these

NGS Library Preparation Kits: Current Scenario and the Future

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as next generation drug conjugates and personalized medicine. However, the conventional nucleotide library preparation process

Oligonucleotide Therapeutics: A Driving Force for CMOs

In the 20th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as Oligonucleotide therapeutics. These short, single-stranded DNA or RNA molecules, which are the product of DNA manufacturing services, have various applications in biopharmaceutical and biotechnology

Gene Editing Technology: ZFN, TALEN and Meganucleases

Presently, there are several companies and universities, which are exploring the potential of gene editing technology beyond CRISPR for basic research, and the development of gene editing solutions. With the development of a versatile gene editing technology, including zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short

ADC Payload / Warheads and Rise in its Demand

With six approved drugs, namely POLIVY™ (2019), LUMOXITI™ (2018), BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011), and more than 300 candidates in the pipeline (clinical / preclinical stages), antibody drug conjugates (ADCs) have emerged as a promising class of therapeutics for the treatment of various disease indications. Over time, medical researchers have